HC Wainwright & Co. Maintains Buy on Moleculin Biotech, Raises Price Target to $22
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Sara Nik maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and raises the price target from $4 to $22.
HC Wainwright & Co. analyst Sara Nik maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and raises the price target from $4 to $22.